Search Results - thereof

11 Results

Sort By:

Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer

This technology includes the development and use of small molecules that inhibit O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) for a variety of pathologies, including Alzheimer's disease, cancer, cancer, diabetes, and neurodegenerative disorders the treatment of cancer and as a potential antiviral. OGT is a ubiquitous enzyme that catalyzes...

Published: 7/25/2024 | Inventor(s): Sara Martin Schwanger, Craig Thomas, Damien Duveau, Suzanne Walker

Keywords(s): 0-GlcNAc, Development, Developmtent, Inhibitors, OGT, THEREOF, TRANSFERASE, USES, VEXXXX, WIXXXX, WKXXXX

Category(s): Application > Research Materials, TherapeuticArea > Neurology, Application > Therapeutics

Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines

CDC researchers have developed a potent immunogenic enhancer polypeptide useful for improving flavivirus vaccines. Flaviviruses such as dengue virus (1, 2, 3 and 4), Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, yellow fever virus and tick-borne encephalitis virus are a great burden on public health. ...

Published: 7/25/2024 | Inventor(s): Holly Hughes, Gwong-Jen Chang

Keywords(s): ADJUSTMENT, adjuvant, Adjuvant-like, BCXXXX, Boost, BOOSTING, CD4, CDC Docket Import, CDC Docket Import CDC Prosecuting, Cell, DB4BXX, DB4XXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DENGUE FEVER, Dengue Vaccine, Dengue-1, Dengue-2, Dengue-Like, DXXXXX, Epitope, Flavivirus, FLAVIVIRUSES, Identification, in vivo, JAPANESE ENCEPHALITIS VIRUS, Listed LPM Houze as of 4/15/2015, Mosquito, Mosquitoes, Nile, OID-NCEZID-DVBD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRIMER, T, THEREOF, Tick-Bone, TICK-BORNE, UBXXXX, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VBXXXX, Vector-borne, Vector-borne diseases, virus, VLXXXX, VOXXXX, WAXXXX, West, WIXXXX, WJXXXX, WMXXXX, XCXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines, Application > Therapeutics, Application > Research Materials, Application > Consumer Products, TherapeuticArea > Infectious Disease

Virus Replicon Particles as Rift Valley Fever Vaccines

Rift Valley fever (RVF) virus primarily infects animals but also has the capacity to infect humans. The disease causes abortion and death among RVF-infected livestock, resulting in substantial economic loss to people living in many parts of Africa and Arabian Peninsula. Currently, there is no commercial vaccine for RVF. CDC scientists have developed...

Published: 7/25/2024 | Inventor(s): Cesar Albarino, Brian Bird, Stuart Nichol, Kimberly Dodd

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, DC5BXX, DC5XXX, DCXXXX, DXXXXX, FEVER, OID-NCEZID-DHCPP, PARTICLES, Replicon, RIFT, THEREOF, Valley, virus, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WFXXXX, WIXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, Application > Occupational Safety and Health, TherapeuticArea > Oncology, TherapeuticArea > Endocrinology, Application > Vaccines, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Dental

Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations

CDC researchers have developed methods of producing unlimited quantities of Group-C (GpC) rotavirus antigens. GpC rotaviruses are a major, worldwide cause of acute gastroenteritis in children and adults that is distinct from Group-A rotavirus. However, GpC rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment...

Published: 7/25/2024 | Inventor(s): Baoming Jiang

Keywords(s): C, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHILDHOOD, Children, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, GROUP, Human, NEONATAL, Neonates, OID-NCIRD-DVD, PARTICLES, rotavirus, Their, THEREOF, viral, Viral-Like, virus, VLXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, ResearchProducts > Antibodies, TherapeuticArea > Cardiology, Application > Research Materials, Application > Occupational Safety and Health, Application > Vaccines, TherapeuticArea > Endocrinology, Application > Diagnostics, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Oncology, Application > Consumer Products, TherapeuticArea > Dental

Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus

This CDC invention relates to primers and probes that specifically hybridize with Heartland virus (HRTLDV), a unique member of the genus Phlebovirus. It further relates to polyclonal antibodies specific for HRTLDV proteins. Serological detection assays using HRTLDV nucleic acid molecules, proteins, probes, primers, and antibodies are provided. Importantly,...

Published: 7/25/2024 | Inventor(s): Stuart Nichol, William Nicholson, Cynthia Goldsmith, Aubree Kelly, Laura McMullan

Keywords(s): AC4XXX, ACXXXX, ANTIBODY, ANTIGEN, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA4BXX, DA4XXX, DAXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Delivery, delivery system, DEVELOPED, diagnostic, DXXXXX, GB2CXX, GB2XXX, GBXXXX, GCXXXX, GENE THERAPY, gene transfer, GXXXXX, heartland, heartland virus, Hospitalized, Identification, ISOLATES, Isolation, Methods, Missouri, Novel, PATHOGENIC, PHLEBOVIRUS, PLATFORM, Platforms, sequence, therapeutic, therapeutic candidates, THEREOF, TICK, TICK-BORNE, TICKS, TWO, Vaccine, VACCINE VECTORS, Vector, Vector-based, Vector-borne, Vector-borne diseases, VETERINARY, VETERINARY vaccine, viral, virus, VLXXXX, VOXXXX, WBXXXX, WDXXXX, WFXXXX, WIXXXX, WJXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo

Category(s): Collaboration Sought > Licensing, ResearchProducts > Antibodies, ResearchProducts > Research Equipment, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Occupational Safety and Health, Application > Consumer Products

Method of Enhancing Opsonophagocytosis

This invention aims to bolster the human body's own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with a disease's specific antibody to enhance systemic bacterial clearance, thus leading...

Published: 7/25/2024 | Inventor(s): GowriSankar Rajam, Sandra Steiner, George Carlone, Nikkol Atwell-Melnick Melnick, Jacquelyn Sampson, Joseph Martinez, Joseph Caba, Edwin Ades

Keywords(s): ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC1XXX, DC4XXX, DCXXXX, DXXXXX, ENHANCING, Epitopes, FUNCTIONAL, Listed LPM Surabian as of 4/15/2015, Methods, OID-NCIRD-DBD, Opsonophagocytosis, PATHOGEN, PNEUMONIAE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PsaA, RESPONSE, Streptococcus, THEREOF, USES

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

Dipicolylamine-based Nanoparticles for Delivery of Ligands

Many potential nucleic acid therapeutics have not transitioned from the research laboratory to clinical application in large part because delivery technologies for these therapies are not effective. Most nucleic acid delivery technologies are lipid-based or positively charged and require chemical or physical conjugation with the nucleic acid. These...

Published: 7/25/2024 | Inventor(s): Seulki Lee, Ki Young Choi, Xiaoyuan (Shawn) Chen

Keywords(s): Acid, DELIVERING, Derivatives, Dipicolylamine, GDXXXX, GXXXXX, Nucleic, THEREOF

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics

Fast Acting Molecular Probes for Real-Time In Vivo Study of Disease and Therapeutics

This technology is for fast acting molecular probes made from a fluorescent quencher molecule, a fluorophore, an enzyme cleavable oligopeptide (for example targeted by protease) and FDA-approved polyethylene glycol (PEG) as well as associated methods to identify cell activity with these probes. Proteases regulate many cell processes such as inflammation...

Published: 7/25/2024 | Inventor(s): Seulki Lee, Lei Zhu, Xiaoyuan (Shawn) Chen

Keywords(s): AA3AXX, AA3XXX, AAXXXX, ACTING, Activity, AXXXXX, Beacon, fast, IMAGING, Molecular, PROTEASE, THEREOF, USES

Category(s): Collaboration Sought > Collaboration

Albumin Binding Immunomodulatory Compositions

The invention relates to molecules wherein Evan’s Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous...

Published: 7/25/2024 | Inventor(s): Guizhi Zhu, Xiaoyuan (Shawn) Chen

Keywords(s): Albumin-binding, Compositions, Immunodulatory, Methods, THEREOF, YAXXXX

Category(s): Collaboration Sought > Licensing

Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E

Hepatitis E virus (HEV) is the cause of Hepatitis E, a liver disease that occurs primarily in developing countries due to fecal contaminated drinking water. Outbreaks of HEV infection have caused epidemics in Africa, Central and Southeast Asia and Mexico and cases of the disease have also been reported sporadically in more developed countries. Hepatitis...

Published: 7/25/2024 | Inventor(s): Suzanne Emerson, Robert Purcell, Xiang-jin Meng

Keywords(s): DC5BXX, DC5XXX, DCXXXX, Duke DNA Project, DXXXXX, e, Hepatitis, Hepatitis A, Hepatitis D, Hepatitis E, HEV, PCT/US98/14665, Swine, THEREOF, UAXXXX, USES, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, TherapeuticArea > Infectious Disease, Application > Vaccines

1 2